Umoja Biopharma Secures FDA IND Clearance for UB-VV400, First-in-Industry CD22-Targeted In Vivo CAR T Cell Therapy for Relapsed/Refractory B-Cell Malignancies

July 26, 2026

Umoja Biopharma (Press Release) USA

Overview

Umoja Biopharma has received FDA Investigational New Drug (IND) clearance for UB-VV400, a CD22-targeted in vivo CAR T cell therapy candidate for relapsed/refractory B-cell malignancies. This marks the industry’s first CD22-targeted in vivo CAR T program, utilizing the VivoVec lentiviral platform to generate CAR T cells directly within the patient. The approach aims to circumvent complex ex vivo manufacturing, potentially enhancing accessibility and reducing costs, with a Phase 1/2 trial planned for Q3 2026.

In Depth

Key Findings

Umoja Biopharma announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for UB-VV400, a CD22-targeted in vivo CAR T cell therapy candidate for relapsed/refractory B-cell malignancies. This milestone represents the industry’s first known CD22-directed in vivo CAR T program, highlighting a potentially transformative shift in the cell therapy paradigm.

Technical / Clinical Details

UB-VV400 is engineered to generate CAR T cells directly within the patient’s body using Umoja Biopharma’s proprietary VivoVec lentiviral platform. This technology bypasses the complex, time-consuming ex vivo manufacturing processes traditionally required for CAR T cell therapies. By eliminating the need for external cell processing, UB-VV400 has the potential to significantly reduce manufacturing costs and logistical burdens, making CAR T cell therapy more accessible and rapidly deployable for a broader patient population. The Phase 1/2 clinical trial, slated to begin in Q3 2026, will assess the safety, tolerability, and preliminary efficacy of UB-VV400. Targeting CD22, which is broadly expressed in B-cell malignancies, offers a promising new option for patients who have relapsed after existing CD19-targeted therapies.

Background & Context

While conventional CAR T cell therapies have delivered breakthrough results for severe hematological cancers, their manufacturing involves several weeks of processing, high costs, and specialized facilities, limiting broad patient access. In vivo CAR T cell therapies are emerging as a next-generation approach to overcome these manufacturing bottlenecks, potentially extending the benefits of CAR T cells to a wider patient demographic. Umoja Biopharma’s UB-VV400 is at the forefront of this innovation, aiming to simplify the therapeutic process and contribute to reducing healthcare costs by generating CAR T cells inside the body.

Strategic Significance & Outlook

The IND clearance for UB-VV400 is a significant advancement for in vivo cell therapies into clinical development, marking a critical milestone in the cell and gene therapy field. If successful, this program could fundamentally alter treatment options for patients with relapsed/refractory B-cell malignancies and democratize access to CAR T cell therapy. Researchers and investors are keenly awaiting initial data from the Phase 1/2 trial, as its outcomes will heavily influence the future viability of in vivo cell therapy platforms and their impact on the biopharmaceutical industry’s business model. The ongoing clinical development holds the key to whether this innovative approach becomes a mainstream cell therapy solution.

Source: https://www.umoja-biopharma.com/news/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.